ВЛИЯНИЕ САХАРОСНИЖАЮЩИЙ ТЕРАПИИ НА ФУНКЦИОНАЛЬНОЕ СОСТОЯНИЕ ПОЧЕК У БОЛЬНЫХ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА.
##article.subject##:
2-tur qandli diabet, protein kinaz C, dipeptidil peptidazalar, tiazolidindionlar, antifibrotik ta'sir.##article.abstract##
Mavzuning dolzarbligi: Qandli diabet kasalligini davolash shifokor uchun ham, bemor uchun ham muammo bo'lib, nafaqat mutaxassislarning yetarli bilim darajasi va bemorlarni xabardor qilish, balki ularning yaqin hamkorligini ham talab qiladi. Kafolatlangan hayot va qat'iy rioya qilingan davolash dasturisiz mumkin bo'lmagan glikemiya darajasini to'g'ri adekvat nazorat qilish xavfli diabet kasalligining oldini olishga, davolanishning sifati va davomiyligini oshirishga imkon beradi.
Библиографические ссылки
Бабенко А.Ю., Байрашева В.К. Диабетическая нефропатия: зависит ли ренопротекция от выбора сахароснижающей терапии? // Медицинский совет. 2015. N. 7. C. 32-43;
Журавлева, О.А. Внутрипочечное сосудистое сопротивление у больных артериальной гипертонией и сахарным диабетом: связь с уровнем артериального давления и величиной скорости клубочковой фильтрации / О.А. Журавлева, И.В. Винницкая, О.А. Кошельская // Сибирский медицинский журнал – 2016. – Т. 31, № 1. – С. 12–21
Шестакова М.В., Халимов Ю.Ш. Результаты исследования ADVANCE и постинтервенционной наблюдательной программы ADVANCE-ON: изменились ли наши представления о взаимосвязи гликемического фактора и риска сосудистых осложнений у больных сахарным диабетом 2 типа? Сахарный диабет. 2015;18(4):119-124. https://doi.org/10.14341/DM7696
Afsar B, Elsurer R. Increased renal resistive index in type 2 diabetes: Clinical relevance, mechanisms and future directions. Diabetes Metab Syndr. 2017 Oct - Dec;11(4):291-296. doi: 10.1016/j.dsx.2016.08.019. Epub 2016 Aug 30.
Barnett AH, Mithal A, Manassie J, et al.; EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol, 2014; 2: 369–384.
Barutta F, Bernardi S, Gargiulo G, Durazzo M, Gruden G. SGLT2 inhibition to address the unmet needs in diabetic nephropathy. Diabetes Metab Res Rev. 2019;35(7):e3171. doi:10.1002/dmrr.3171
Carrillo-Larco RM, Barengo NC, Albitres-Flores L, Bernabe-Ortiz A. The risk of mortality among people with type 2 diabetes in Latin America: A systematic review and meta-analysis of population-based cohort studies. Diabetes Metab Res Rev. 2019 May;35(4):e3139.
Cellular and molecular mechanisms of metformin: an overview / B.Viollet [et al.] // ClinSci (Lond). - 2012. - Vol. 122, № 6. - P. 253-270. Diabetic kidney disease: worldwide difference of prevalence and risk factors / O.Gheith [et al.] // J Nephropharmacol. - 2015. - Vol. 5, № 1. - P. 49-56.
Ceriello A, Rossi MC, De Cosmo S, et al. Overall quality of care predicts the variability of key risk factors for complications in type 2 diabetes: an observational. Longitudinal Retrospective Study Diabetes Care. 2019; 42(4): 514‐ 519.
Einarson, T.R., Acs, A., Ludwig, C. et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 17, 83 (2018). https://doi.org/10.1186/s12933-018-0728-6
Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2015;5(1):49-56.
Haluzík M, Frolík J, Rychlík I. Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria. Int J Endocrinol. 2013;2013:895102. doi:10.1155/2013/895102
Kim DI, Park MJ, Heo YR, Park SH. Metformin ameliorates lipotoxicity-induced mesangial cell apoptosis partly via upregulation of glucagon like peptide-1 receptor (GLP-1R). Arch Biochem Biophys. 2015 Oct 15; 584:90-7. doi: 10.1016/j.abb.2015.08.009.
Kim J.H. Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication // Kidney Res. Clin. Pract. – 2017. –Vol. 36, N 1. – P. 58–67
Kim, S.S. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients // Diabetes Res Clin Pract. - 2012. - Vol. 97, № 2. - P. 251-257.
Korbut A.I., Klimontov V.V. Empagliflozin: a new strategy for nephroprotection in diabetes. Diabetes mellitus. 2017;20(1):75-84. (In Russ.) https://doi.org/10.14341/DM8005
Li Z., Liu H., Niu et al. // Temporal Proteomic Analysis of Pancreatic β-Cells in Response to Lipotoxicity and Glucolipotoxicity // Molecular and cellular proteomics.- 2018.- Vol.17.- № 11.- P.2119-2131.
McFarlane P, Cherney D, Gilbert RE, Senior P. Chronic Kidney Disease in Diabetes. Can J Diabetes. 2018 Apr;42 Suppl 1:201-209.
McGill JB. The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review. Diabet Ther. 2014;5(1):43-63. doi: 10.1007/s13300-014-0063-1.
McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139(3):351–61.
Murkamilov IT, Sabirov IS, Fomin VV, Murkamilova ZhA, Yusupov FА, Rayimzhanov ZR. Modern methods of slowing down the progression of chronic kidney disease in type 2 diabetes mellitus. The Bulletin of Contemporary Clinical Medicine. 2020; 13 (4): 76-85.
Ong KL, Waters DD, Fayyad R, Vogt L, Melamed S, DeMicco DA, Rye KA, Barter PJ. Relationship of High-Density Lipoprotein Cholesterol with Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc. 2018 Jan 22;7(2):e007387. doi: 10.1161/JAHA.117.007387.
Reichetzeder C., von Websky K., Tsuprykov O., Mohagheghi Samarin A., Falke L.G., Dwi Putra S.E. et al. (2017) Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury. Br. J. Pharmacol. 174, 2273–2286
Scheen AJ, Delanaye P. Renal outcomes with iDPP-4. Diabetes Metab. 2018 Mar;44(2):101-111.
Williams-Herman D., Xu L., Teng R. et al. Effect of initial combination therapy with sitagliptin and metformin on -cell function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2018;14(1):67–76
Zaccardi F., Webb D., Htike Z., et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis // Diabetes Obes. Metab., 2016. Vol. 18(8). Pp. 783-794
